Aptus Capital Advisors LLC Purchases 940 Shares of Novo Nordisk A/S (NYSE:NVO)

Aptus Capital Advisors LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 33.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,774 shares of the company’s stock after acquiring an additional 940 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $449,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of NVO. GQG Partners LLC raised its stake in shares of Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after acquiring an additional 3,151,584 shares in the last quarter. International Assets Investment Management LLC grew its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC grew its position in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Acadian Asset Management LLC grew its position in Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after purchasing an additional 1,155,313 shares during the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Stock Down 3.4 %

NVO stock opened at $101.74 on Friday. The firm’s fifty day simple moving average is $119.17 and its 200-day simple moving average is $129.75. The company has a market capitalization of $456.56 billion, a P/E ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.